Acute treatment with valproic acid and L-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats

Neurobiology of Disease

Volumn 71, Issue 1, 2014, Pages 220-233

  Castelo Branco, Gonçalo ^a   Stridh, Pernilla ^a   Guerreiro Cacais, André Ortlieb ^a   Adzemovic, Milena Z ^a,b   Falcão, Ana Mendanha ^a   Marta, Monica ^a,c   Berglund, Rasmus ^a   Gillett, Alan ^a   Hamza, Kedir Hussen ^a   Lassmann, Hans ^b   Hermanson, Ola ^a   Jagodic, Maja ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Epigenetics; Experimental autoimmune encephalomyelitis; Histone deacetylases; Immune system; Multiple sclerosis; Myelin; Neuroinflammation; Oligodendrocyte precursor; T cells; Thyroid hormone

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON; INTERLEUKIN 17; LEVOTHYROXINE; LIOTHYRONINE; MYELIN; TRANSCRIPTION FACTOR FOXP3; VALPROIC ACID; CD11B ANTIGEN; ENZYME INHIBITOR; KI 67 ANTIGEN; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN 68-88; PEPTIDE FRAGMENT; THYROXINE;

ACUTE DRUG ADMINISTRATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BRAIN; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL LINEAGE; CELLULAR IMMUNITY; CLINICAL FEATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DARK AGOUTI RAT; DEMYELINATION; DOWN REGULATION; DRUG POTENTIATION; ENCEPHALITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MALE; MYELIN GENE; NONHUMAN; RAT; SPINAL CORD; TREATMENT DURATION; WEIGHT REDUCTION; ANALYSIS OF VARIANCE; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD11B; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; FLOW CYTOMETRY; INTERLEUKIN-17; KI-67 ANTIGEN; MYELIN BASIC PROTEIN; PEPTIDE FRAGMENTS; RATS; THYROXINE; VALPROIC ACID;

EID: 84908156379     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.08.019     Document Type: Article

References (61)

1. Baron J.L., Madri J.A., Ruddle N.H., Hashim G., Janeway C.A. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 1993, 177:57-68.
2. Brogdon J.L., Xu Y., Szabo S.J., An S., Buxton F., Cohen D., Huang Q. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007, 109:1123-1130.
3. Camelo S., Iglesias A.H., Hwang D., Due B., Ryu H., Smith K., Gray S.G., Imitola J., Duran G., Assaf B., et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 164:10-21.
4. Campas-Moya C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today 2009, 45:787-795.
5. Castelo-Branco G., Lilja T., Wallenborg K., Falcao A.M., Marques S.C., Gracias A., Solum D., Paap R., Walfridsson J., Teixeira A.I., et al. Neural stem cell differentiation is dictated by distinct actions of nuclear receptor corepressors and histone deacetylases. Stem Cell Reports 2014, 3:1-14.
6. Chiu C.T., Wang Z., Hunsberger J.G., Chuang D.M. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol. Rev. 2013, 65:105-142.
7. Codarri L., Gyulveszi G., Tosevski V., Hesske L., Fontana A., Magnenat L., Suter T., Becher B. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 2011, 12:560-567.
8. Colello R.J., Sato-Bigbee C. Purification of oligodendrocytes and their progenitors using immunomagnetic separation and Percoll gradient centrifugation. Curr. Protoc. Neurosci. 2001, 3:12-14. (editorial board, Jacqueline N Crawley [et al] Chapter 1-3, Unit 3.12).
9. Dagtas A.S., Edens R.E., Gilbert K.M. Histone deacetylase inhibitor uses p21(Cip1) to maintain anergy in CD4+ T cells. Int. Immunopharmacol. 2009, 9:1289-1297.
10. De Vito P., Incerpi S., Pedersen J.Z., Luly P., Davis F.B., Davis P.J. Thyroid hormones as modulators of immune activities at the cellular level. Thyroid 2011, 21:879-890.
11. de Zoeten E.F., Wang L., Sai H., Dillmann W.H., Hancock W.W. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 2010, 138:583-594.
12. Deshmukh V.A., Tardif V., Lyssiotis C.A., Green C.C., Kerman B., Kim H.J., Padmanabhan K., Swoboda J.G., Ahmad I., Kondo T., et al. A regenerative approach to the treatment of multiple sclerosis. Nature 2013, 502:327-332.
13. Edens R.E., Dagtas S., Gilbert K.M. Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int. Immunopharmacol. 2006, 6:1673-1681.
14. Fancy S.P., Chan J.R., Baranzini S.E., Franklin R.J., Rowitch D.H. Myelin regeneration: a recapitulation of development?. Annu. Rev. Neurosci. 2011, 34:21-43.
15. Fernandez M., Giuliani A., Pirondi S., D'Intino G., Giardino L., Aloe L., Levi-Montalcini R., Calza L. Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:16363-16368.
16. Ge Z., Da Y., Xue Z., Zhang K., Zhuang H., Peng M., Li Y., Li W., Simard A., Hao J., et al. Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Exp. Neurol. 2013, 241:56-66.
17. Gerstner T., Bell N., Konig S. Oral valproic acid for epilepsy-long-term experience in therapy and side effects. Expert Opin. Pharmacother. 2008, 9:285-292.
18. Glauben R., Batra A., Fedke I., Zeitz M., Lehr H.A., Leoni F., Mascagni P., Fantuzzi G., Dinarello C.A., Siegmund B. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 2006, 176:5015-5022.
19. Goverman J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 2009, 9:393-407.
20. Hirota K., Duarte J.H., Veldhoen M., Hornsby E., Li Y., Cua D.J., Ahlfors H., Wilhelm C., Tolaini M., Menzel U., et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 2011, 12:255-263.
21. Iglesias A., Bauer J., Litzenburger T., Schubart A., Linington C. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 2001, 36:220-234.
22. IMSGC Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
23. + glial cells. Nat. Neurosci. 2013, 16:1401-1408.
24. Kramer O.H., Knauer S.K., Greiner G., Jandt E., Reichardt S., Guhrs K.H., Stauber R.H., Bohmer F.D., Heinzel T. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 2009, 23:223-235.
25. Kroenke M.A., Carlson T.J., Andjelkovic A.V., Segal B.M. IL-12-and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 2008, 205:1535-1541.
26. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
27. Lee C.G., Kwon H.K., Sahoo A., Hwang W., So J.S., Hwang J.S., Chae C.S., Kim G.C., Kim J.E., So H.S., et al. Interaction of Ets-1 with HDAC1 represses IL-10 expression in Th1 cells. J. Immunol. 2012, 188:2244-2253.
28. Leoni F., Fossati G., Lewis E.C., Lee J.K., Porro G., Pagani P., Modena D., Moras M.L., Pozzi P., Reznikov L.L., et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 2005, 11:1-15.
29. Lin H.S., Hu C.Y., Chan H.Y., Liew Y.Y., Huang H.P., Lepescheux L., Bastianelli E., Baron R., Rawadi G., Clement-Lacroix P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 2007, 150:862-872.
30. Lucas J.L., Mirshahpanah P., Haas-Stapleton E., Asadullah K., Zollner T.M., Numerof R.P. Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell. Immunol. 2009, 257:97-104.
31. Lv J., Du C., Wei W., Wu Z., Zhao G., Li Z., Xie X. The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis. J. Biol. Chem. 2012, 287:28656-28665.
32. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
33. Mishra N., Reilly C.M., Brown D.R., Ruiz P., Gilkeson G.S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 2003, 111:539-552.
34. Moreira J.M., Scheipers P., Sorensen P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 2003, 3:30.
35. Nait-Oumesmar B., Picard-Riera N., Kerninon C., Decker L., Seilhean D., Hoglinger G.U., Hirsch E.C., Reynolds R., Baron-Van Evercooren A. Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4694-4699.
36. Nakahara J., Seiwa C., Tan-Takeuchi K., Gotoh M., Kishihara K., Ogawa M., Asou H., Aiso S. Involvement of CD45 in central nervous system myelination. Neurosci. Lett. 2005, 379:116-121.
37. Nishida K., Komiyama T., Miyazawa S., Shen Z.N., Furumatsu T., Doi H., Yoshida A., Yamana J., Yamamura M., Ninomiya Y., et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 2004, 50:3365-3376.
38. Olsson T., Zhi W.W., Hojeberg B., Kostulas V., Jiang Y.P., Anderson G., Ekre H.P., Link H. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J. Clin. Invest. 1990, 86:981-985.
39. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., Wang Y., Hood L., Zhu Z., Tian Q., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6:1133-1141.
40. Perissi V., Jepsen K., Glass C.K., Rosenfeld M.G. Deconstructing repression: evolving models of co-repressor action. Nat. Rev. Genet. 2010, 11:109-123.
41. Rafalski V.A., Ho P.P., Brett J.O., Ucar D., Dugas J.C., Pollina E.A., Chow L.M., Ibrahim A., Baker S.J., Barres B.A., et al. Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain. Nat. Cell Biol. 2013, 15:614-624.
42. H-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 2009, 10:514-523.
43. Saouaf S.J., Li B., Zhang G., Shen Y., Furuuchi N., Hancock W.W., Greene M.I. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 2009, 87:99-104.
44. Sebastian C., Serra M., Yeramian A., Serrat N., Lloberas J., Celada A. Deacetylase activity is required for STAT5-dependent GM-CSF functional activity in macrophages and differentiation to dendritic cells. J. Immunol. 2008, 180:5898-5906.
45. Segal B.M., Shevach E.M. IL-12 unmasks latent autoimmune disease in resistant mice. J. Exp. Med. 1996, 184:771-775.
46. Shen S., Sandoval J., Swiss V.A., Li J., Dupree J., Franklin R.J., Casaccia-Bonnefil P. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat. Neurosci. 2008, 11:1024-1034.
47. Song W., Tai Y.T., Tian Z., Hideshima T., Chauhan D., Nanjappa P., Exley M.A., Anderson K.C., Munshi N.C. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 2011, 25:161-168.
48. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60:12-21.
49. Stolt C.C., Lommes P., Friedrich R.P., Wegner M. Transcription factors Sox8 and Sox10 perform non-equivalent roles during oligodendrocyte development despite functional redundancy. Development 2004, 131:2349-2358.
50. Storch M.K., Stefferl A., Brehm U., Weissert R., Wallstrom E., Kerschensteiner M., Olsson T., Linington C., Lassmann H. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 1998, 8:681-694.
51. H17 cells. Nat. Med. 2008, 14:337-342.
52. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., Li B., Turka L.A., Olson E.N., Greene M.I., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 2007, 13:1299-1307.
53. Tepavcevic V., Lazarini F., Alfaro-Cervello C., Kerninon C., Yoshikawa K., Garcia-Verdugo J.M., Lledo P.M., Nait-Oumesmar B., Baron-Van Evercooren A. Inflammation-induced subventricular zone dysfunction leads to olfactory deficits in a targeted mouse model of multiple sclerosis. J. Clin. Invest. 2011, 121:4722-4734.
54. Villagra A., Cheng F., Wang H.W., Suarez I., Glozak M., Maurin M., Nguyen D., Wright K.L., Atadja P.W., Bhalla K., et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol. 2009, 10:92-100.
55. Vinken P.I., Bruyn G.W. The neuropathology of multiple sclerosis. Handbook of Clinical Neurology 1970, 217-309. Elsevier, New York.
56. von Budingen H.C., Tanuma N., Villoslada P., Ouallet J.C., Hauser S.L., Genain C.P. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. J. Clin. Immunol. 2001, 21:155-170.
57. Wang J., Weaver I.C., Gauthier-Fisher A., Wang H., He L., Yeomans J., Wondisford F., Kaplan D.R., Miller F.D. CBP histone acetyltransferase activity regulates embryonic neural differentiation in the normal and Rubinstein-Taybi syndrome brain. Dev. Cell 2010, 18:114-125.
58. Ye F., Chen Y., Hoang T., Montgomery R.L., Zhao X.H., Bu H., Hu T., Taketo M.M., van Es J.H., Clevers H., et al. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat. Neurosci. 2009, 12:829-838.
59. Zawadzka M., Rivers L.E., Fancy S.P., Zhao C., Tripathi R., Jamen F., Young K., Goncharevich A., Pohl H., Rizzi M., et al. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell 2010, 6:578-590.
60. Zhang Z.Y., Zhang Z., Schluesener H.J. MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neuroscience 2010, 169:370-377.
61. Zhang Z., Zhang Z.Y., Wu Y., Schluesener H.J. Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats. Neuroscience 2012, 221:140-150.